{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 105 of 169', 'procedure and analysis will be conducted in the same way as described for the primary', 'analysis of the secondary estimand for the continuous secondary endpoints.', '12.3.5.3 Analysis of additional secondary endpoints', 'To support the primary endpoints, EASI50 at Week 16, EASI90 at Week 16 and the change', 'from baseline to Week 16 in EASI score will be analysed and presented for the full analysis', 'set. EASI50 and EASI90 will be analysed as described for the primary analysis of the primary', 'estimand for the primary endpoints, and the change from baseline to Week 16 will be analysed', 'as described for the primary analysis of the primary estimand for the continuous secondary', 'endpoints.', 'To support the secondary endpoints on severity and extent of AD, at least 75% reduction in', 'SCORAD score (SCORAD75) at Week 16, and SCORAD50 at Week 16 will be analysed and', 'presented for the full analysis set. Both endpoints will be analysed as described for the', 'primary analysis of the primary estimand for the primary endpoints.', 'To support the secondary endpoint on worst daily itch, the change from baseline to Week 16', 'in Worst Daily Pruritus NRS weekly average and the reduction of Worst Daily Pruritus NRS', 'weekly average of at least 3 (from baseline to Week 16) will be analysed and presented for the', 'full analysis set. The change from baseline to Week 16 in Worst Daily Pruritus NRS weekly', 'average will be analysed as described for the primary analysis of the primary estimand for the', 'continuous secondary endpoints. The reduction of Worst Daily Pruritus NRS weekly average', 'of at least 3 (from baseline to Week 16) is a binary endpoint and will be analysed as described', 'for the primary analysis of the primary estimand for the primary endpoints.', 'To support the secondary endpoint on HQoL, the binary endpoint reduction from baseline to', 'Week 16 of DLQI of>4 points will be analysed and presented for the subjects in the full', 'analysis set with a baseline DLQI >4 similarly to the analysis described for the primary', 'analysis of the primary estimand for the primary endpoints.', '12.3.5.4 Analysis of other endpoints', '12.3.5.4.1 Efficacy over time', 'To further pursue the objectives supported by the five Week 16 endpoints in the confirmatory', 'test hierarchy, these endpoints (as well as the change in Worst Daily Pruritus NRS [weekly', 'average]) will be evaluated at each scheduled assessment up to Week 14 or each week up to', 'Week 15:', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 106 of 169', 'IGA( 0/1 at each scheduled assessment until Week 14.', 'EASI75 at each scheduled assessment until Week 14.', 'Change in SCORAD from baseline to each scheduled assessment until', 'Week 14.', 'Change from baseline to each week through Week 1 to 15 in Worst Daily', 'Pruritus NRS (weekly average).', 'Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4 from', 'baseline to each week through Week 1 to 15.', 'Change in DLQI score from baseline to each scheduled assessment until', 'Week 14.', 'Nominal p-values for test of a treatment difference and 95% CI for the difference will be', 'presented at each scheduled visit (or each week for Worst Daily Pruritus NRS) using the same', 'approach as applied for the primary analysis of the relevant endpoint in the primary estimand.', 'For the binary endpoints, the same Cochran-Mantel-Haenszel test as for the Week 16', 'assessment will be applied. For the continuous endpoints, the repeated measurements model', 'already described previously for the Week 16 assessments facilitates that the p-values,', 'treatment differences and 95% CIs can be derived for each visit up to Week 14 (or Week 15', 'for the change in Worst Daily Pruritus NRS) in the same analysis that already will be made', 'for the corresponding Week 16 assessments.', '12.3.5.4.2 Patient-reported outcomes', 'The PROs POEM, DLQI, EQ-5D-5L, SF-36, WPAI-GH, HADS, and TSQM will be', 'summarised by treatment group and visit using descriptive statistics. The summaries will be', 'made separately for the initial treatment and the maintenance treatment. Data from the initial', 'treatment period will be presented for the full analysis set and data from the maintenance', 'treatment period will be presented for the maintenance analysis set.', 'The PROs collected in the eDiaries on a daily basis (Worst Daily Pruritus NRS, Average Daily', 'Pruritus NRS, Eczema-related Sleep NRS, PGI-B, and PGI-S) will all be summarised over', 'time by treatment group using descriptive statistics. The summaries will be separate for the', 'initial treatment and the maintenance treatment. Data from the initial treatment period will be', 'presented for the full analysis set and data from the maintenance treatment period will be', 'presented for the maintenance analysis set.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}